4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch NowZacks Investment Research • 10/20/26
Prediction: $1,000 Invested in Viking Therapeutics Today Will Be Worth This Much in 5 YearsThe Motley Fool • 10/20/26
Viking Therapeutics Initiates Pivotal Phase 3 Trial: Here's Why Investors Have Reason for Optimism After a Disappointing Phase 2The Motley Fool • 10/20/26
Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter.The Motley Fool • 10/18/26
Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy?Zacks Investment Research • 10/14/26
Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with ObesityPRNewsWire • 10/14/26
Novo Down 11% in a Month: How Should Investors Approach the Stock Now?Zacks Investment Research • 10/12/26
Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call.The Motley Fool • 10/12/26
Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock?The Motley Fool • 10/10/26
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to ConsiderZacks Investment Research • 10/09/26
Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should KnowZacks Investment Research • 10/08/26
Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with ObesityPRNewsWire • 10/06/26
LLY Highlights New Efficacy Data From Foundayo and EloraTZP StudiesZacks Investment Research • 10/02/26
Should You Buy Viking Therapeutics Stock While It Trades Below Its $35 Offering Price?The Motley Fool • 10/02/26
Viking Therapeutics, Inc. (VKTX) Stock Declines While Market Improves: Some Information for InvestorsZacks Investment Research • 10/01/26
Viking Therapeutics, Inc. (VKTX) Rises As Market Takes a Dip: Key FactsZacks Investment Research • 09/30/26
Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.The Motley Fool • 09/30/26
Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why.The Motley Fool • 09/29/26
Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior NotesPRNewsWire • 09/28/26